Form 4: Quest Diagnostics SVP & General Counsel Reports Stock Transactions
SEC Form 4 Filing
Michael E. Prevoznik, SVP & General Counsel of Quest Diagnostics, reports the acquisition and disposal of company stock, including transactions to cover tax obligations and sales under a Rule 10b5-1 plan.
Summary
- Michael E. Prevoznik, SVP & General Counsel of Quest Diagnostics, filed a Form 4 detailing changes in beneficial ownership of the company's stock.
- On March 3, 2025, Mr. Prevoznik disposed of 322 shares at $173.74 to cover tax withholding obligations from vesting restricted stock units.
- On March 4, 2025, he sold 592 shares at $175.79 under a pre-arranged Rule 10b5-1 sales plan.
- Also on March 4, 2025, Mr. Prevoznik acquired 8,549 shares at $173.74 related to a performance stock award.
- He disposed of 3,906 shares at $173.74 to cover tax withholding obligations from the settlement of the performance stock award.
- Mr. Prevoznik also indirectly owns 5,640 shares through the company's 401(k)/SDCP.
- Following these transactions, Mr. Prevoznik directly owns 42,760 shares and indirectly owns 5,640 shares.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment about the company's performance.
Industry Context
Form 4 filings are a routine part of insider trading regulations, providing transparency into the buying and selling activities of company executives and directors. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.
Comparison to Industry Standards
- Comparing these transactions to similar filings from executives at comparable diagnostic companies like Labcorp (LH) or Bio-Rad Laboratories (BIO) would provide context.
- For example, if other executives in the industry are also selling shares under 10b5-1 plans, it might suggest a broader trend related to personal financial planning rather than company-specific concerns.
- Similarly, comparing the size and frequency of stock awards to industry benchmarks can help assess the competitiveness of Quest Diagnostics' executive compensation practices.
Stakeholder Impact
- The transactions may have a minor impact on shareholders by slightly increasing the float.
- The transactions have no direct impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 03/03/2025 | Disposition of 322 shares to cover tax withholding obligations. |
| 03/04/2025 | Sale of 592 shares under Rule 10b5-1 plan, acquisition of 8,549 shares from performance stock award, and disposition of 3,906 shares to cover tax obligations from the award. |
| 03/05/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.